Advances in breast cancer treatment: 2016 prospect

Speaker: Thomas Bachelot

T. Bachelot elaborates the results from the studies presented at ASCO Annual Meeting 2016. The results from MA.17R show that extended adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor reduces contralateral breast cancer. He also discusses the results from MONARCH1 of CDK4/6 monotherapy in advanced setting.

Discussion Points

  • Rationale for the study
  • Key study findings
  • Practice perspective

Abstract  LBA1: A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.                                                          

Abstract 510: MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.